Q4 2025 · 13F-HR
Octagon Capital Advisors LPholdings as filed
Filed 2026-02-17 · accession 0001839435-26-000002
$823.7M
Reported value
27
Positions
2025-12-31
Period end
The Brief · Octagon Capital Advisors LP · Q4 2025
AI · grounded in 13F
Octagon Capital Advisors LP closed its position in Merus N V 2GH, reducing exposure by $28.99M. The fund established new positions in CG Oncology Inc CGON for $24.91M and Alumis Inc ALMS for $24.69M. Additionally, the fund exited Apellis Pharmaceuticals Inc APLSUSD with a $20.44M reduction and increased its stake in Kymera Therapeutics Inc KYMR by 48.61%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 00370M103 | ABVX | ABIVAX SA | $102.0M | 12.4% | 756,000 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $99.6M | 12.1% | 2,416,667 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $83.5M | 10.1% | 2,350,000 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $48.7M | 5.92% | 8,859,911 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $43.1M | 5.24% | 13,915,371 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $41.6M | 5.05% | 535,000 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $39.7M | 4.81% | 1,971,054 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $35.2M | 4.28% | 2,815,000 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $31.9M | 3.87% | 2,623,600 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $29.9M | 3.63% | 2,230,000 | Common | SOLE |
| 156944100 | CGON | CG ONCOLOGY INC | $24.9M | 3.02% | 600,000 | CALL | SOLE |
| 022307102 | ALMS | ALUMIS INC | $24.7M | 3.00% | 2,530,700 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $22.5M | 2.73% | 9,567,898 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $22.1M | 2.68% | 100,000 | Common | SOLE |
| 09077V100 | BIOA | BIOAGE LABS INC | $21.1M | 2.57% | 1,598,000 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $20.6M | 2.50% | 1,273,333 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $19.4M | 2.36% | 574,000 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $18.8M | 2.28% | 750,000 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $18.6M | 2.26% | 671,465 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $17.1M | 2.08% | 1,725,000 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $13.1M | 1.59% | 1,043,110 | Common | SOLE |
| 23306J309 | DBVT | DBV TECHNOLOGIES S A | $11.0M | 1.34% | 574,200 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $8.6M | 1.04% | 500,000 | Common | SOLE |
| 74019P207 | DTIL | PRECISION BIOSCIENCES INC | $8.0M | 0.97% | 1,917,995 | Common | SOLE |
| 21833P301 | CRBP | CORBUS PHARMACEUTICALS HLDGS | $7.8M | 0.94% | 955,000 | Common | SOLE |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $5.8M | 0.70% | 1,000,000 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $4.6M | 0.55% | 700,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.